Delft-based OASYS NOW, a company that offers patient-centric Clinical Trial technology solutions and healthcare data management, has secured fresh funding (undisclosed) from Amsterdam’s VC firm ASIF Ventures.
ASIF Ventures aims to empower student and recent graduate-founded startups in the Amsterdam Metropolitan Area. With funding ranging from €25K to €100K, ASIF bridges the gap between student entrepreneurs and VC funding.
The problem OASYS is trying to solve
OASYS claims to play a pivotal role in addressing a crucial challenge faced by drug development companies—identifying suitable candidates for clinical trials and research studies.
This is significant for patients with life-threatening chronic and rare diseases who need timely access to new treatment options.
Currently, the process of matching patients with appropriate treatments is manual, laborious, and inefficient, costing drug research organisations millions of euros and, unfortunately, precious lives every year.
OASYS aims to revolutionise this process, bringing efficiency to drug development and potentially saving lives by providing timely access to new treatment options.
The company was founded in 2018 by Nima Salami, Sara Okhuijsen, and Viktor Koppenol.
OASYS NOW’s GRIP platform
OASYS NOW launched its GRIP platform last month (in November), developed in collaboration with academic medical centres and patient organisations.
The platform addresses challenges for patients with rare or chronic conditions. Serving as a digital waiting room, GRIP empowers individuals by providing access to up-to-date information on new medicines and clinical trials.
By taking control of their electronic health records, patients bridge the gap between medical advancements and their journey.
Additionally, OASYS NOW aims to streamline eligibility assessments for drug development companies through GRIP technology.
This digital approach reduces the need for multiple in-person visits, automating the comparison between patients’ health records and trial criteria. The goal is to expedite and simplify the evaluation of new medicines’ suitability for individual patients in clinical trials.
GRIP also tackles delays in trial recruitment by enhancing the alignment between patient profiles and research studies.
01
Tech meets private credit: Demystifying Norsad Capital’s efficiency boost with PE Front Office